59 related articles for article (PubMed ID: 38753638)
1. Identifying the mechanism of polysaccharopeptide against breast cancer based on network pharmacology and experimental verification.
Xu C; Sun L; Wang H; Sun J; Feng Y; Wang X; Song Z
BMC Cancer; 2024 Jun; 24(1):726. PubMed ID: 38872110
[TBL] [Abstract][Full Text] [Related]
2. Identification of potential anti-tumor targets and mechanisms of HuaChanSu injection using network pharmacology and cytological experiments in Breast cancer.
Yang Z; Wang Y; Huang S; Geng Y; Yang Z; Yang Z
PLoS One; 2024; 19(5):e0303650. PubMed ID: 38753638
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory Impact Of Cinobufagin In Triple-Negative Breast Cancer Metastasis: Involvements Of Macrophage Reprogramming Through Upregulated MME and Inactivated FAK/STAT3 Signaling.
Zhu Z; Wang H; Qian X; Xue M; Sun A; Yin Y; Tang J; Zhang J
Clin Breast Cancer; 2024 Jun; 24(4):e244-e257.e1. PubMed ID: 38378361
[TBL] [Abstract][Full Text] [Related]
4. Sanyin Formula Enhances the Therapeutic Efficacy of Paclitaxel in Triple-Negative Breast Cancer Metastases through the JAK/STAT3 Pathway in Mice.
Wu C; Sun C; Han X; Ye Y; Qin Y; Liu S
Pharmaceuticals (Basel); 2022 Dec; 16(1):. PubMed ID: 36678509
[TBL] [Abstract][Full Text] [Related]
5. [Traditional Chinese medicine network pharmacology: development in new era under guidance of network pharmacology evaluation method guidance].
Wang ZY; Wang X; Zhang DY; Hu YJ; Li S
Zhongguo Zhong Yao Za Zhi; 2022 Jan; 47(1):7-17. PubMed ID: 35178906
[TBL] [Abstract][Full Text] [Related]
6. Cinobufagin induces FOXO1-regulated apoptosis, proliferation, migration, and invasion by inhibiting G9a in non-small-cell lung cancer A549 cells.
Zhang L; Liang B; Xu H; Gong Y; Hu W; Jin Z; Wu X; Chen X; Li M; Shi L; Shi Y; Wang Y; Yang L
J Ethnopharmacol; 2022 Jun; 291():115095. PubMed ID: 35176466
[TBL] [Abstract][Full Text] [Related]
7. HuaChanSu suppresses tumor growth and interferes with glucose metabolism in hepatocellular carcinoma cells by restraining Hexokinase-2.
Wu Q; Wang SP; Sun XX; Tao YF; Yuan XQ; Chen QM; Dai L; Li CL; Zhang JY; Yang AL
Int J Biochem Cell Biol; 2022 Jan; 142():106123. PubMed ID: 34826616
[TBL] [Abstract][Full Text] [Related]
8. Drug Resistance in Metastatic Breast Cancer: Tumor Targeted Nanomedicine to the Rescue.
Gote V; Nookala AR; Bolla PK; Pal D
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925129
[TBL] [Abstract][Full Text] [Related]
9. PI3K/AKT/mTOR signalling pathway involvement in renal cell carcinoma pathogenesis (Review).
Miricescu D; Balan DG; Tulin A; Stiru O; Vacaroiu IA; Mihai DA; Popa CC; Papacocea RI; Enyedi M; Sorin NA; Vatachki G; Georgescu DE; Nica AE; Stefani C
Exp Ther Med; 2021 May; 21(5):540. PubMed ID: 33815613
[TBL] [Abstract][Full Text] [Related]
10. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Sung H; Ferlay J; Siegel RL; Laversanne M; Soerjomataram I; Jemal A; Bray F
CA Cancer J Clin; 2021 May; 71(3):209-249. PubMed ID: 33538338
[TBL] [Abstract][Full Text] [Related]
11. Unlocking the Mystery of the Therapeutic Effects of Chinese Medicine on Cancer.
Liu SH; Chen PS; Huang CC; Hung YT; Lee MY; Lin WH; Lin YC; Lee AY
Front Pharmacol; 2020; 11():601785. PubMed ID: 33519464
[TBL] [Abstract][Full Text] [Related]
12. PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects.
Miricescu D; Totan A; Stanescu-Spinu II; Badoiu SC; Stefani C; Greabu M
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33375317
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and anti-tumor activities of carbamate derivatives of cinobufagin.
Zhou Y; Hou J; Long H; Zhang Z; Lei M; Wu W
Steroids; 2020 Dec; 164():108749. PubMed ID: 33065151
[TBL] [Abstract][Full Text] [Related]
14. Safety reassessment of cinobufotalin injection: new findings into cardiotoxicity.
Li M; Wang X; Qiu Y; Zhang Y; Pan X; Tang N; Chen T; Ruan B; Shao S; He L; Li H; Ma J
Toxicol Res (Camb); 2020 Jul; 9(4):390-398. PubMed ID: 32905219
[TBL] [Abstract][Full Text] [Related]
15. Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer.
Nunnery SE; Mayer IA
Drugs; 2020 Nov; 80(16):1685-1697. PubMed ID: 32894420
[TBL] [Abstract][Full Text] [Related]
16. Immune system activation by natural products and complex fractions: a network pharmacology approach in cancer treatment.
Gomez-Cadena A; Barreto A; Fioretino S; Jandus C
Cell Stress; 2020 May; 4(7):154-166. PubMed ID: 32656498
[TBL] [Abstract][Full Text] [Related]
17. Network Pharmacology Study on the Pharmacological Mechanism of Cinobufotalin Injection against Lung Cancer.
Mao Y; Peng X; Xue P; Lu D; Li L; Zhu S
Evid Based Complement Alternat Med; 2020; 2020():1246742. PubMed ID: 32148531
[TBL] [Abstract][Full Text] [Related]
18. Cinobufagin induces cell cycle arrest at the S phase and promotes apoptosis in nasopharyngeal carcinoma cells.
Pan Z; Luo Y; Xia Y; Zhang X; Qin Y; Liu W; Li M; Liu X; Zheng Q; Li D
Biomed Pharmacother; 2020 Feb; 122():109763. PubMed ID: 31918288
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
